Clinical workflow fit
Test how the product fits existing German clinical pathways, procedures and decision points.
Germany Market Entry
Entering Germany requires more than appointing a distributor. TAUR Medical helps international MedTech companies validate clinical adoption, market access, reference-centre potential and the right commercial model before committing significant resources — and can execute the launch locally.
The German opportunity
Germany is one of the largest medical device markets in Europe and an early reference for clinical adoption across the region. It is also complex: clinical adoption, reimbursement and market access, hospital procurement, local evidence, reference centres and route-to-market must be considered together — not in isolation.
International MedTech companies that enter Germany on distribution alone often discover too late that clinical validation, access strategy and local execution were never resolved. TAUR addresses these together, so the route into the German medical device market is validated before major resources are committed.
Clinical adoption
German clinicians decide adoption — their input must shape the route.
Reimbursement & access
Coverage, pricing and procurement shape the viable launch model.
Local evidence
Real-world evidence and PMCF often support adoption and coverage.
Reference centres
Early clinical advocates build credibility and momentum.
Procurement
Hospital buying processes and tenders influence timing and channel.
Route-to-market
Distributor, hybrid or local execution — chosen against reality.
Clinical validation
TAUR structures product-specific input from relevant German clinicians and KOLs to test adoption assumptions before launch decisions are made.
Test how the product fits existing German clinical pathways, procedures and decision points.
Identify the structural and behavioural barriers that could slow German adoption before launch.
Pressure-test the clinical and economic value proposition with the physicians who decide adoption.
Assess where clinical advocates and reference centres could emerge in the German system.
Structured input from relevant German clinicians and KOLs — not a simple survey or desk research.
Clinical validation is the first stage of TAUR's Germany approach. See how it connects to clinical evidence and PMCF for products that require structured real-world data.
Market access
Reimbursement, hospital economics, procurement and access requirements can materially influence the appropriate launch model. TAUR brings a market-access perspective to the route-to-market decision — so access realities shape the plan rather than appearing as obstacles after launch.
TAUR does not guarantee reimbursement outcomes. Access pathways are product- and evidence-specific, and reimbursement strategy must be validated against the German context for each device.
Reimbursement pathway
Map the relevant coverage route and pricing signal for the product.
Hospital economics
Understand the economics that drive adoption and buying decisions.
Procurement & tenders
Anticipate hospital procurement processes and tender requirements.
Evidence requirements
Identify the evidence payers and hospitals will expect.
Credibility & adoption
Early reference centres, clinicians and expert validation can support market credibility and adoption across the German system. TAUR identifies where clinical advocates could emerge and develops those relationships into structured reference-centre support — not a contact list, but engaged physicians who help shape and champion adoption.
Identify reference-centre potential
Map where clinical advocates and reference sites could emerge.
Engage relevant KOLs
Structured dialogue with the physicians who influence adoption.
Build clinical credibility
Turn expert feedback into evidence and reference relationships.
Support adoption
Reference centres that help later customers decide.
Route-to-market
There is no single correct model. The appropriate route depends on the product, evidence position, market maturity and existing European infrastructure.
A qualified distributor carries sales, logistics and customer relationships. Fastest to start, but depends heavily on partner focus, capability and performance management.
A distributor handles volume and logistics while TAUR or the manufacturer retains KOL engagement, reference centres and key accounts directly.
TAUR provides local commercial execution — KOL activation, reference centres, key accounts and customer development — without building a full German subsidiary on day one.
TAUR helps international manufacturers choose and validate the right model — and can deliver the local execution layer where a distributor alone is not enough.
The TAUR model
One integrated route — assess the opportunity, validate and launch with the German market, then build and scale through local commercial execution.
German market, competitors, access landscape and commercial potential — sized against your portfolio and evidence position.
Clinical experts, KOLs, reference centres, evidence planning and launch priorities — validated with the German market before commitment.
Partner management, key accounts, customer development and local commercial execution — turning the plan into German revenue.
Why TAUR
Senior German commercial execution, a German clinical expert and KOL network, and one integrated route from validation to launch.
Experienced MedTech commercial leadership — not junior consultants handing over a slide deck.
Direct access to the clinicians and KOLs whose adoption decisions shape the German market.
Reimbursement, procurement and access realities built into the route-to-market from the start.
Early reference centres and clinical advocates that build credibility and support adoption.
On-the-ground commercial execution in Germany — customers, partners and key accounts activated locally.
A single accountable partner from validation through launch to commercial scale — not fragmented vendors.
Next step
Start with a focused Germany discussion or use the Market Entry Navigator if you are still assessing readiness.